Antibody-drug conjugates (ADCs) and bispecific antibodies were the stars of the recent American Society of Clinical Oncology (ASCO) meeting, where Chinese companies had a major presence this year and accounted for close to half of all the presentations across the two modalities at the 30 May-3 June event in Chicago.
Innovent Biologics was one of the major Chinese firms showcasing its assets, including IBI363, a first-in-class anti-PD-1/IL-2α-bias bispecific which, if...